The primary objective of this study is to evaluate the efficacy of ALO-01 compared with placebo for the treatment of chronic moderate to severe pain (focusing on osteoarthritis of the hip or knee) as measured by mean change in diary Brief Pain Inventory (BPI) score of average pain (daily scores of average pain averaged over 7 days) from randomization to 12 weeks following randomization.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT00420992?cond=%22Arthritis%22&lup_s=08/23/2013&lup_d=30
